 Dual PPAR agonists have been considered as potential therapeutics for the treatment of type 2 diabetes mellitus . After comprehensive structureactivity relationship study based on GFT505 a novel dual PPAR agonist compound

@highlight Compound
@highlight shows higher selectivity to PPAR and lower agonistic activity on PPAR.
@highlight Compound
@highlight exerts dose dependent anti diabetic effects in
@highlight mice.
@highlight Compound
@highlight reveals similar potency to GFT505 the most advanced candidate in this field.
@highlight The obtained SAR in this study might help us to explore better PPAR agonist.
